Paulo Miranda

Statistics

Publications

Citations

242

H-Index

Active since

2007

Affiliations

AstraZeneca (United States)(Current)

Vita-Salute San Raffaele University

Dana-Farber Cancer Institute

The Ohio State University

IRCCS Ospedale San Raffaele

Paulo Miranda is an author at AstraZeneca (United States) specializing in chronic lymphocytic leukemia therapy, relapsed chronic lymphocytic leukemia, and pharmacology.

ORCID

Publications per year

2007–2025

Publications

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial

John F. Seymour, John C. Byrd, Paolo Ghia et al. · Blood · 2023 · 119 citations · Full text

Medicine, Oncology, Pharmacology +13

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN

Jeff P. Sharman, Miklós Egyed, Wojciech Jurczak et al. · Blood · 2025 · 36 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

A cost evaluation of treatment alternatives for mild‐to‐moderate bleeding episodes in patients with haemophilia and inhibitors in Brazil

Margareth C. Ozelo, Paula Ribeiro Villaça, J. O. S. C DE ALMEIDA et al. · Haemophilia · 2007 · 34 citations · Full text

Pharmacy, Hematology, Pharmacoeconomics +14

Acute Coronary Syndrome Treatment Costs from the Perspective of the Supplementary Health System

Vanessa Teich, Tony Piha, L. Fahham et al. · Arquivos Brasileiros de Cardiologia · 2015 · 26 citations · Full text

Pharmacy, Cardiology, Pharmacoeconomics +17

Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials

Matthew S. Davids, Jeff P. Sharman, Paolo Ghia et al. · Blood Advances · 2024 · 17 citations · Full text

Medicine, Oncology, Pharmacology +13

1–5 of 6